News

March 28, 2019

Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas

News

Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a ... Read more

March 26, 2019

Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma

News

Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma ... Read more

March 22, 2019March 22, 2019

Scotland Rejects NHS Access to Kymriah for Aggressive Diffuse Large B-cell Lymphoma

News

Scotland’s healthcare system has rejected the use of Novartis‘ immunotherapy Kymriah (tisagenlecleucel) for adults with aggressive diffuse large B-cell lymphoma (DLBCL) who failed at least two prior lines of therapy. The Scottish Medicines Consortium ... Read more

March 21, 2019

PD-L1 Levels, Response to Tecentriq Linked in Younger Cancer Patients

News

Children, adolescents, and young adults with relapsed or refractory cancers — particularly those with lymphoma — have better responses to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) if they have ... Read more

March 19, 2019

CTCL Patients Who Continue Treatment Use Fewer Hospital Resources, Study Says

News

Patients with cutaneous T-cell lymphoma (CTCL) who for some reason discontinue their systemic treatments require more monthly emergency room visits, hospital admissions, and longer inpatient stays than those who ... Read more

March 15, 2019

Phase 1/2 Trial of Tinostamustine to Treat Blood Cancers Opens 2nd Stage

News

The expansion stage of a Phase 1/2 trial testing tinostamustine in relapsed or refractory types of lymphoma and other blood cancers has enrolled a first patient. The study (NCT02576496) is ... Read more

March 13, 2019

Gamida Cell’s Therapy Shows Promise for Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Gamida Cell’s natural killer cell treatment is a promising approach to treat adults with relapsed or refractory non-Hodgkin’s lymphoma or multiple myeloma, according to early data from an ongoing Phase 1 clinical ... Read more

March 12, 2019

Cell Medica Earns $8.7 Million Grant to Accelerate Off-the-shelf CAR-NKT Cell Therapy

News

Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an ... Read more

March 8, 2019March 8, 2019

Physician Stephen J. Forman Receives Top Honors for Research on Bone Marrow Transplantation

News

Stephen J. Forman, MD, a physician and researcher in bone marrow transplantation and disorders such as lymphoma, is racking up some accolades. Forman will receive the 2019 DKMS Mechtild ... Read more

March 7, 2019

$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies

News

The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to ... Read more

Pin It on Pinterest